Literature DB >> 19931429

Sirtuins inhibitors: the approach to affinity and selectivity.

Yana Cen1.   

Abstract

Accumulating evidence has indicated the importance of sirtuins (class III histone deacetylases) in various biological processes. Their potential roles in metabolic and neurodegenerative diseases have encouraged scientists to seek potent and selective sirtuin inhibitors to investigate their biological functions with a view to eventual new therapeutic treatments. This article surveys current knowledge of sirtuin inhibitors including those discovered via high-throughput screening (HST) or via mechanism-based drug design from synthetic or natural sources. Their inhibitory affinity, selectivities, and possible inhibition mechanisms are discussed. Copyright 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19931429     DOI: 10.1016/j.bbapap.2009.11.010

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  29 in total

1.  SIRT1 contains N- and C-terminal regions that potentiate deacetylase activity.

Authors:  Min Pan; Hua Yuan; Michael Brent; Emily Chen Ding; Ronen Marmorstein
Journal:  J Biol Chem       Date:  2011-12-07       Impact factor: 5.157

2.  SIRT1 enzymatically potentiates 1,25-dihydroxyvitamin D3 signaling via vitamin D receptor deacetylation.

Authors:  Marya S Sabir; Zainab Khan; Chengcheng Hu; Michael A Galligan; Christopher M Dussik; Sanchita Mallick; Angelika Dampf Stone; Shane F Batie; Elizabeth T Jacobs; G Kerr Whitfield; Mark R Haussler; Michael C Heck; Peter W Jurutka
Journal:  J Steroid Biochem Mol Biol       Date:  2017-06-19       Impact factor: 4.292

3.  SIRT2 plays a significant role in maintaining the survival and energy metabolism of PIEC endothelial cells.

Authors:  Jie Zhang; Caixia Wang; Hui Nie; Danhong Wu; Weihai Ying
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2016-09-30

Review 4.  Using mitochondrial sirtuins as drug targets: disease implications and available compounds.

Authors:  Melanie Gertz; Clemens Steegborn
Journal:  Cell Mol Life Sci       Date:  2016-03-23       Impact factor: 9.261

5.  SIRT1 is a critical regulator of K562 cell growth, survival, and differentiation.

Authors:  Mark T Duncan; Teresa A DeLuca; Hsin-Yu Kuo; Minchang Yi; Milan Mrksich; William M Miller
Journal:  Exp Cell Res       Date:  2016-04-13       Impact factor: 3.905

Review 6.  Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer.

Authors:  K Ted Thurn; Scott Thomas; Amy Moore; Pamela N Munster
Journal:  Future Oncol       Date:  2011-02       Impact factor: 3.404

Review 7.  Translating cell survival and cell longevity into treatment strategies with SIRT1.

Authors:  K Maiese; Z Z Chong; Yan Chen Shang; S Wang
Journal:  Rom J Morphol Embryol       Date:  2011       Impact factor: 1.033

Review 8.  Sirtuin activators and inhibitors: Promises, achievements, and challenges.

Authors:  Han Dai; David A Sinclair; James L Ellis; Clemens Steegborn
Journal:  Pharmacol Ther       Date:  2018-03-22       Impact factor: 12.310

9.  Design of a novel nucleoside analog as potent inhibitor of the NAD dependent deacetylase, SIRT2.

Authors:  Padavattan Sivaraman; Suresh Mattegunta; Gottumukkala V Subbaraju; Chava Satyanarayana; Balasundaram Padmanabhan
Journal:  Syst Synth Biol       Date:  2011-02-23

10.  Sirtuin Deacetylation Mechanism and Catalytic Role of the Dynamic Cofactor Binding Loop.

Authors:  Yawei Shi; Yanzi Zhou; Shenglong Wang; Yingkai Zhang
Journal:  J Phys Chem Lett       Date:  2013-02-07       Impact factor: 6.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.